← Leaderboards
Michael A Caligiuri
Ohio State University
$65,062,344
Attributed
$72,506,817
Total exposure
37
Grants
29
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $15.8M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$185,106,210 · 40
By mechanism
P30$87,680,887 · 13
P01$53,938,424 · 10
R01$12,316,871 · 5
R35$7,377,660 · 1
T32$7,282,201 · 1
U10$7,123,860 · 1
Top collaborators
- Jianhua Yu13 shared
- E. Antonio Chiocca11 shared
- Lihua Elizabeth Budde5 shared
- Mine Cicek2 shared
- Wendy Frankel2 shared
- William G Richards2 shared
- Mark A Watson2 shared
Most similar at Ohio State University
Same institution · by research overlap
- Balveen Kaur$17,543,202
- Bethany Mundy-Bosse$1,809,973
- Christopher C. Oakes$2,619,311
- Charles L Shapiro$2,281,818
- Michael C Ostrowski$13,472,116
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsFundingProgramsClinical ResearchMemberCancer Center Support GrantGrantBasic ScienceUniversitiesNatural Killer CellsResearch PersonnelClinical TrialsResourcesLaboratoriesResource SharingBaseOhioCollaborationsTranslational ResearchSuccessGrowthSolid NeoplasmStrategic PlanningInvestments
Grant awards (200)
Human natural killer cells: Advancing biology and clinical applications$886,438
R35 · FY2025 · CA · contact PI
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia$489,159
R01 · FY2025 · CA · contact PI
Project 4: Awakening immune responses to GBM by enhancing immune cell trafficking and activation with oHSV armed with Cetuximab-CCL5 and anti-CD47 antibody payloads.$335,203
P01 · FY2025 · CA · contact PI
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia$464,700
R01 · FY2024 · CA · contact PI
Project 4: Awakening immune responses to GBM by enhancing immune cell trafficking and activation with oHSV armed with Cetuximab-CCL5 and anti-CD47 antibody payloads.$318,443
P01 · FY2024 · CA · contact PI
An engineered oncolytic herpes virus expressing a full-length α-CD47 mAb for the treatment of GBM$250,210
U19 · FY2024 · CA · contact PI
Human natural killer cells: Advancing biology and clinical applications$954,486
R35 · FY2023 · CA · contact PI
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia$479,375
R01 · FY2023 · CA · contact PI
Project 4: Awakening immune responses to GBM by enhancing immune cell trafficking and activation with oHSV armed with Cetuximab-CCL5 and anti-CD47 antibody payloads.$354,954
P01 · FY2023 · CA · contact PI
Circumventing barriers to effective oncolytic virotherapy of malignant gliomas$1,766,381
P01 · FY2022 · CA
Human natural killer cells: Advancing biology and clinical applications$954,486
R35 · FY2022 · CA · contact PI
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia$479,375
R01 · FY2022 · CA · contact PI
Project 4: Modulating the natural killer cell response to oHSV1 in recurrent human GBM$313,545
P01 · FY2022 · CA · contact PI
Circumventing barriers to effective oncolytic virotherapy of malignant gliomas$1,789,540
P01 · FY2021 · CA
Human natural killer cells: Advancing biology and clinical applications$973,964
R35 · FY2021 · CA · contact PI
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia$489,159
R01 · FY2021 · CA · contact PI
Project 4: Modulating the natural killer cell response to oHSV1 in recurrent human GBM$319,944
P01 · FY2021 · CA · contact PI
Circumventing barriers to effective oncolytic virotherapy of malignant gliomas$1,777,058
P01 · FY2020 · CA
DEVELOPMENTAL FUNDS (Core 002)$1,142,799
P30 · FY2020 · CA · contact PI
Human natural killer cells: Advancing biology and clinical applications$973,964
R35 · FY2020 · CA · contact PI
ADMINISTRATION (Admin Core)$660,495
P30 · FY2020 · CA · contact PI
Project 4: Modulating the natural killer cell response to oHSV1 in recurrent human GBM$319,944
P01 · FY2020 · CA · contact PI
PLANNING AND EVALUATION (Core 001)$94,315
P30 · FY2020 · CA · contact PI
Circumventing barriers to effective oncolytic virotherapy of malignant gliomas$1,717,653
P01 · FY2019 · CA
DEVELOPMENTAL FUNDS (Core 002)$1,147,399
P30 · FY2019 · CA · contact PI
Human natural killer cells: Advancing biology and clinical applications$712,108
R35 · FY2019 · CA · contact PI
ADMINISTRATION (Admin Core)$665,094
P30 · FY2019 · CA · contact PI
Enhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer Prevention$383,865
R01 · FY2019 · CA
IL-15 Characterization Through Experimental Immunology$334,667
R01 · FY2019 · CA
Project 4: Modulating the natural killer cell response to oHSV1 in recurrent human GBM$310,345
P01 · FY2019 · CA · contact PI
PLANNING AND EVALUATION (Core 001)$98,915
P30 · FY2019 · CA · contact PI
Circumventing barriers to effective oncolytic virotherapy of malignant gliomas$1,905,452
P01 · FY2018 · CA
DEVELOPMENTAL FUNDS (Core 002)$997,689
P30 · FY2018 · CA · contact PI
Human natural killer cells: Advancing biology and clinical applications$992,214
R35 · FY2018 · CA · contact PI
ADMINISTRATION (Admin Core)$586,793
P30 · FY2018 · CA · contact PI
Enhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer Prevention$352,275
R01 · FY2018 · CA
Project 4: Modulating the natural killer cell response to oHSV1 in recurrent human GBM$339,694
P01 · FY2018 · CA · contact PI
IL-15 Characterization Through Experimental Immunology$175,175
R01 · FY2018 · CA
IL-15 Characterization Through Experimental Immunology$154,000
R01 · FY2018 · CA
PLANNING AND EVALUATION (Core 001)$104,431
P30 · FY2018 · CA · contact PI
Cancer Center Support Grant$59,783
P30 · FY2018 · CA · contact PI
ADMINISTRATION (Admin Core)$4,573
P30 · FY2018 · CA · contact PI
PLANNING AND EVALUATION (Core 001)$4,572
P30 · FY2018 · CA · contact PI
DEVELOPMENTAL FUNDS (Core 002)$4,572
P30 · FY2018 · CA · contact PI
ADMINISTRATION (Admin Core)$2,401
P30 · FY2018 · CA · contact PI
PLANNING AND EVALUATION (Core 001)$2,399
P30 · FY2018 · CA · contact PI
DEVELOPMENTAL FUNDS (Core 002)$2,399
P30 · FY2018 · CA · contact PI
ADMINISTRATION (Admin Core)$2,392
P30 · FY2018 · CA · contact PI
PLANNING AND EVALUATION (Core 001)$2,391
P30 · FY2018 · CA · contact PI
DEVELOPMENTAL FUNDS (Core 002)$2,391
P30 · FY2018 · CA · contact PI
ADMINISTRATION (Admin Core)$2,024
P30 · FY2018 · CA · contact PI
PLANNING AND EVALUATION (Core 001)$2,023
P30 · FY2018 · CA · contact PI
DEVELOPMENTAL FUNDS (Core 002)$2,022
P30 · FY2018 · CA · contact PI
Cancer Center Support Grant$5,040,816
P30 · FY2017 · CA · contact PI
DEVELOPMENTAL FUNDS (Core 002)$996,007
P30 · FY2017 · CA · contact PI
Human natural killer cells: Advancing biology and clinical applications$930,000
R35 · FY2017 · CA · contact PI
ADMINISTRATION (Admin Core)$577,340
P30 · FY2017 · CA · contact PI
Enhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer Prevention$352,275
R01 · FY2017 · CA · contact PI
IL-15 Characterization Through Experimental Immunology$329,175
R01 · FY2017 · CA
NK Innate Immunity and Oncolytic Virus Therapy$251,009
P01 · FY2017 · CA · contact PI
Cancer Center Support Grant$200,000
P30 · FY2017 · CA · contact PI
Cancer Center Support Grant$139,874
P30 · FY2017 · CA · contact PI
Cancer Center Support Grant$125,000
P30 · FY2017 · CA · contact PI
PLANNING AND EVALUATION (Core 001)$85,861
P30 · FY2017 · CA · contact PI
Cancer Center Support Grant$5,040,816
P30 · FY2016 · CA · contact PI
THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCE$2,228,496
U24 · FY2016 · CA
Innate Immunity: Elucidation and Modulation for Cancer Therapy$2,048,056
P01 · FY2016 · CA · contact PI
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$1,682,938
P01 · FY2016 · CA · contact PI
ADMINISTRATION (Admin Core)$859,289
P30 · FY2016 · CA · contact PI
DEVELOPMENTAL FUNDS (Core 002)$781,532
P30 · FY2016 · CA · contact PI
Cancer Center Support Grant$498,265
P30 · FY2016 · CA · contact PI
Oncology Training Grant$488,813
T32 · FY2016 · CA · contact PI
Enhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer Prevention$352,275
R01 · FY2016 · CA · contact PI
NATURAL KILLER CELLS: ACQUISITION OF CD16 AND REGULATION OF NEGATIVE SIGNALING$335,892
P01 · FY2016 · CA · contact PI
IL-15 Characterization Through Experimental Immunology$329,175
R01 · FY2016 · CA · contact PI
NK Innate Immunity and Oncolytic Virus Therapy$247,976
P01 · FY2016 · CA · contact PI
Cancer Center Support Grant$200,000
P30 · FY2016 · CA · contact PI
Cancer Center Support Grant$200,000
P30 · FY2016 · CA · contact PI
Cancer Center Support Grant$198,176
P30 · FY2016 · CA · contact PI
ADMINISTRATION, BUDGETING AND OPERATIONS$158,670
P01 · FY2016 · CA · contact PI
Cancer Center Support Grant$125,000
P30 · FY2016 · CA · contact PI
PLANNING AND EVALUATION (Core 001)$67,375
P30 · FY2016 · CA · contact PI
Cancer Center Support Grant$4,582,303
P30 · FY2015 · CA · contact PI
THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCE$3,327,369
U24 · FY2015 · CA
Innate Immunity: Elucidation and Modulation for Cancer Therapy$2,048,056
P01 · FY2015 · CA · contact PI
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$1,655,598
P01 · FY2015 · CA · contact PI
Developmental Funds$880,490
P30 · FY2015 · CA · contact PI
Oncology Training Grant$501,216
T32 · FY2015 · CA · contact PI
Enhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer Prevention$352,275
R01 · FY2015 · CA · contact PI
NATURAL KILLER CELLS: ACQUISITION OF CD16 AND REGULATION OF NEGATIVE SIGNALING$335,892
P01 · FY2015 · CA · contact PI
IL-15 Characterization Through Experimental Immunology$329,175
R01 · FY2015 · CA · contact PI
NK Innate Immunity and Oncolytic Virus Therapy$242,793
P01 · FY2015 · CA · contact PI
Protocol-Specific Research Support$236,585
P30 · FY2015 · CA · contact PI
ADMINISTRATION, BUDGETING AND OPERATIONS$158,670
P01 · FY2015 · CA · contact PI
Senior Leadership$142,047
P30 · FY2015 · CA · contact PI
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$105,672
P01 · FY2015 · CA · contact PI
Program Leaders$92,488
P30 · FY2015 · CA · contact PI
Cancer Center Support Grant$62,500
P30 · FY2015 · CA · contact PI
Cancer Center Support Grant$60,126
P30 · FY2015 · CA · contact PI
Planning and Evaluation$41,769
P30 · FY2015 · CA · contact PI
Cancer Center Support Grant$31,250
P30 · FY2015 · CA · contact PI
Cancer Center Support Grant$4,444,835
P30 · FY2014 · CA · contact PI
Innate Immunity: Elucidation and Modulation for Cancer Therapy$1,986,616
P01 · FY2014 · CA · contact PI
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$1,612,546
P01 · FY2014 · CA · contact PI
Developmental Funds$845,302
P30 · FY2014 · CA · contact PI
Oncology Training Grant$464,434
T32 · FY2014 · CA · contact PI
NATURAL KILLER CELLS: ACQUISITION OF CD16 AND REGULATION OF NEGATIVE SIGNALING$325,816
P01 · FY2014 · CA · contact PI
IL-15 characterization through experimental immunology$265,837
R37 · FY2014 · CA · contact PI
NK Innate Immunity and Oncolytic Virus Therapy$235,606
P01 · FY2014 · CA · contact PI
Protocol-Specific Research Support$229,118
P30 · FY2014 · CA · contact PI
ADMINISTRATION, BUDGETING AND OPERATIONS$153,910
P01 · FY2014 · CA · contact PI
Cancer Center Support Grant$149,838
P30 · FY2014 · CA · contact PI
Senior Leadership$138,652
P30 · FY2014 · CA · contact PI
Cancer Center Support Grant$135,233
P30 · FY2014 · CA · contact PI
Cancer Center Support Grant$125,000
P30 · FY2014 · CA · contact PI
Program Leaders$91,225
P30 · FY2014 · CA · contact PI
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$89,527
P01 · FY2014 · CA · contact PI
Cancer Center Support Grant$75,000
P30 · FY2014 · CA · contact PI
Planning and Evaluation$42,690
P30 · FY2014 · CA · contact PI
Cancer Center Support Grant$4,284,455
P30 · FY2013 · CA · contact PI
Innate Immunity: Elucidation and Modulation for Cancer Therapy$1,927,708
P01 · FY2013 · CA · contact PI
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$1,721,925
P01 · FY2013 · CA · contact PI
Developmental Funds$814,803
P30 · FY2013 · CA · contact PI
Oncology Training Grant$383,240
T32 · FY2013 · CA · contact PI
NATURAL KILLER CELLS: ACQUISITION OF CD16 AND REGULATION OF NEGATIVE SIGNALING$316,102
P01 · FY2013 · CA · contact PI
NK Innate Immunity and Oncolytic Virus Therapy$312,775
P01 · FY2013 · CA · contact PI
Pre-Clinical and Clinical Investigation of MLL-PTD Acute Myeloid Leukemia$262,796
P50 · FY2013 · CA · contact PI
Functional Characterization of MLL Gene Fusions$261,369
R01 · FY2013 · CA · contact PI
IL-15 characterization through experimental immunology$258,118
R37 · FY2013 · CA · contact PI
Protocol-Specific Research Support$220,850
P30 · FY2013 · CA · contact PI
ADMINISTRATION, BUDGETING AND OPERATIONS$149,512
P01 · FY2013 · CA · contact PI
Senior Leadership$133,650
P30 · FY2013 · CA · contact PI
Senior Leadership$121,802
P30 · FY2013 · CA · contact PI
Cancer Center Support Grant$121,802
P30 · FY2013 · CA · contact PI
Program Leaders$87,934
P30 · FY2013 · CA · contact PI
Planning and Evaluation$41,151
P30 · FY2013 · CA · contact PI
Cancer Center Support Grant$12,500
P30 · FY2013 · CA · contact PI
Senior Leadership$12,500
P30 · FY2013 · CA · contact PI
Cancer Center Support Grant$4,582,303
P30 · FY2012 · CA · contact PI
Innate Immunity: Elucidation and Modulation for Cancer Therapy$2,058,483
P01 · FY2012 · CA · contact PI
Developmental Funds$871,443
P30 · FY2012 · CA · contact PI
Oncology Training Grant$487,428
T32 · FY2012 · CA · contact PI
NATURAL KILLER CELLS: ACQUISITION OF CD16 AND REGULATION OF NEGATIVE SIGNALING$337,382
P01 · FY2012 · CA · contact PI
Pre-Clinical and Clinical Investigation of MLL-PTD Acute Myeloid Leukemia$280,698
P50 · FY2012 · CA · contact PI
Functional Characterization of MLL Gene Fusions$278,052
R01 · FY2012 · CA · contact PI
IL-15 characterization through experimental immunology$275,144
R37 · FY2012 · CA · contact PI
Protocol-Specific Research Support$236,205
P30 · FY2012 · CA · contact PI
ADMINISTRATION, BUDGETING AND OPERATIONS$160,160
P01 · FY2012 · CA · contact PI
Senior Leadership$142,937
P30 · FY2012 · CA · contact PI
Cancer Center Support Grant$140,000
P30 · FY2012 · CA · contact PI
Program Leaders$94,042
P30 · FY2012 · CA · contact PI
Cancer Center Support Grant$75,000
P30 · FY2012 · CA · contact PI
Cancer Center Support Grant$49,250
P30 · FY2012 · CA · contact PI
Planning and Evaluation$44,009
P30 · FY2012 · CA · contact PI
Functional Characterization of MLL Gene Fusions$16,829
R01 · FY2012 · CA · contact PI
Cancer Center Support Grant$4,582,303
P30 · FY2011 · CA · contact PI
Innate Immunity: Elucidation and Modulation for Cancer Therapy$2,012,576
P01 · FY2011 · CA · contact PI
Oncology Training Grant$447,905
T32 · FY2011 · CA · contact PI
ELUCIDATION & MODULATION OF NATURAL KILLER CELL SIGNALING: APPLICATION IN CANCER$409,266
P01 · FY2011 · CA · contact PI
Functional Characterization of MLL Gene Fusions$278,052
R01 · FY2011 · CA · contact PI
IL-15 characterization through experimental immunology$275,708
R37 · FY2011 · CA · contact PI
Pre-Clinical and Clinical Investigation of MLL-PTD Acute Myeloid Leukemia$266,429
P50 · FY2011 · CA · contact PI
Cancer Center Support Grant$140,000
P30 · FY2011 · CA · contact PI
Cancer Center Support Grant$49,250
P30 · FY2011 · CA · contact PI
Functional Characterization of MLL Gene Fusions$16,501
R01 · FY2011 · CA · contact PI
Cancer Center Support Grant$10,000
P30 · FY2011 · CA · contact PI
The Ohio State University Comprehensive Cancer Center$3,823,791
P30 · FY2010 · CA · contact PI
Innate Immunity: Elucidation and Modulation for Cancer Therapy$2,080,062
P01 · FY2010 · CA · contact PI
ELUCIDATION & MODULATION OF NATURAL KILLER CELL SIGNALING: APPLICATION IN CANCER$423,497
P01 · FY2010 · CA · contact PI
Oncology Training Grant$414,165
T32 · FY2010 · CA · contact PI
Functional Characterization of MLL Gene Fusions$286,652
R01 · FY2010 · CA · contact PI
IL-15 characterization through experimental immunology$284,840
R37 · FY2010 · CA · contact PI
Pre-Clinical and Clinical Investigation of MLL-PTD Acute Myeloid Leukemia$280,251
P50 · FY2010 · CA · contact PI
The Ohio State University Comprehensive Cancer Center$200,000
P30 · FY2010 · CA · contact PI
The Ohio State University Comprehensive Cancer Center$100,000
P30 · FY2010 · CA · contact PI
The Ohio State University Comprehensive Cancer Center$80,000
P30 · FY2010 · CA · contact PI
The Ohio State University Comprehensive Cancer Center$50,000
P30 · FY2010 · CA · contact PI
Functional Characterization of MLL Gene Fusions$17,007
R01 · FY2010 · CA · contact PI
The Ohio State University Comprehensive Cancer Center$3,956,712
P30 · FY2009 · CA · contact PI
Innate Immunity: Elucidation and Modulation for Cancer Therapy$2,044,559
P01 · FY2009 · CA · contact PI
The Ohio State University Comprehensive Cancer Center$1,472,500
P30 · FY2009 · CA · contact PI
Developmental Funds$960,595
P30 · FY2009 · CA · contact PI
Cancer and Leukemia Group B - Leukemia Correlative Sciences$861,611
U10 · FY2009 · CA · contact PI
Oncology Training Grant$463,640
T32 · FY2009 · CA · contact PI
ELUCIDATION & MODULATION OF NATURAL KILLER CELL SIGNALING: APPLICATION IN CANCER$416,782
P01 · FY2009 · CA · contact PI
Senior Leadership$304,701
P30 · FY2009 · CA · contact PI
Functional Characterization of MLL Gene Fusions$286,652
R01 · FY2009 · CA · contact PI
Pre-Clinical and Clinical Investigation of MLL-PTD Acute Myeloid Leukemia$278,237
P50 · FY2009 · CA · contact PI
IL-15 Characterization Through Experimental Immunology$271,102
R01 · FY2009 · CA · contact PI
Protocol Specific Research Support$239,172
P30 · FY2009 · CA · contact PI
The Ohio State University Comprehensive Cancer Center$89,606
P30 · FY2009 · CA · contact PI
Program Planning & Evaluation$52,381
P30 · FY2009 · CA · contact PI
The Ohio State University Comprehensive Cancer Center$50,000
P30 · FY2009 · CA · contact PI
Functional Characterization of MLL Gene Fusions$25,821
R01 · FY2009 · CA · contact PI
The Ohio State University Comprehensive Cancer Center$3,753,703
P30 · FY2008 · CA · contact PI
Innate Immunity: Elucidation and Modulation for Cancer Therapy$2,003,446
P01 · FY2008 · CA · contact PI
Cancer and Leukemia Group B-Leukemia Correlative Science$1,000,836
U10 · FY2008 · CA · contact PI
Developmental Funds$911,661
P30 · FY2008 · CA · contact PI
ELUCIDATION & MODULATION OF NATURAL KILLER CELL SIGNALING: APPLICATION IN CANCER$404,651
P01 · FY2008 · CA · contact PI
Oncology Training Grant$396,719
T32 · FY2008 · CA · contact PI